Startups
BIND Therapeutics is a biotechnology company incorporated in 2006; Pfizer acquired substantially all of its assets in 2016.
BIND’s product candidates were based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS®, which continue to be developed with Pfizer, have the potential to achieve therapeutic outcomes not currently possible with conventional treatment modalities.
BIND’s product candidates were based on proprietary polymeric nanoparticles called ACCURINS®, which are engineered to target specific cells and tissues in the body at sites of disease. ACCURINS®, which continue to be developed with Pfizer, have the potential to achieve therapeutic outcomes not currently possible with conventional treatment modalities.
Overview
Location
United States, Massachusetts, Cambridge
Employees
51-200
Total raised
$22M
Founded date
2006
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 3, 2016 | Biotech bankruptcies, a trip to the Vatican, and Adam Feuerstein’s favorite bar | Welcome to Kendall Squared, a twice-weekly newsletter bringing you exclusive news and analysis from biotech’s hotbed in Cambridge, Mass. Last week, I accidentally sent you two broken links. Rest assured I have been adequately punished. If y... |
| Feb 10, 2016 | Nano-caging gives a failed cancer drug new life | Kendall Squared brings you dispatches from the world’s epicenter for biotechnology and drug discovery. BIND Therapeutics describes itself as bringing nanotechnology to cancer therapy, but with an achievement announced on Wednesday a more co... |
| Jul 15, 2015 | New drug delivery methods are making taking medicine easier for everyone | Three dimensional printing technology is becoming more and more popular, from creating prosthetics to artificial organs. That same technology is also being used to create a new way to deliver medication. Aprecia Pharmaceuticals in Langhorne... |
| Sep 23, 2013 | Langer brainchild Bind Therapeutics launches $70.5M IPO | Serial entrepreneur and Massachusetts biotech super-star Dr. Robert Langer’s Bind Therapeutics last week launched an initial public offering aimed at raising $70.5 million from shares sold at $15 apiece. The clinical-stage company, co-found... |
| Aug 28, 2013 | 11 health companies make the World Economic Group tech pioneer list | Nearly one-third of the 36 emerging technology pioneers chosen by the World Economic Forum this year have implications for the life sciences and health IT space. They represent robotics, noninvasive prenatal testing, using edible identifier... |
| New drug delivery methods are making taking medicine easier for everyone | Whether it’s a child unable to swallow a pill or someone who has a strong fear of needles, getting the right medication to the right person can sometimes be a bit more difficult than you think it should be. Needle fearers and anti-pill advo... | |
| 11 health companies make the World Economic Group tech pioneer list | Nearly one-third of the 36 emerging technology pioneers chosen by the World Economic Forum this year have implications for the life sciences and health IT space. They represent robotics, noninvasive prenatal testing, using edible identifier... |
Reviews 0
FAQ about BIND Therapeutics
When was BIND Therapeutics founded?
BIND Therapeutics was founded in 2006.
How much funding has BIND Therapeutics raised?
BIND Therapeutics has raised $22M in total across 1 funding round.
What has the press written about BIND Therapeutics?
Parsers VC has collected 8 articles mentioning BIND Therapeutics, among them “Biotech bankruptcies, a trip to the Vatican, and Adam Feuerstein’s favorite bar” (May 3, 2016) and “Nano-caging gives a failed cancer drug new life” (Feb 10, 2016).
Is BIND Therapeutics still active?
BIND Therapeutics is probably closed: its latest activity on Parsers VC dates from Jul 27, 2016.